Expanding Treatment Options for Metastatic Breast Cancer : Episode 6

Compliance and Adherence to Therapy in mBC

Apr 22, 2020

Transcript:

Related Videos

Colin E. Champ, MD

Expert on breast cancer

Expert on breast cancer

Christie J. Hilton, D

Lida A. Mina, MD

Expert on breast cancer

Expert on breast cancer

Karen S. Anderson, MD, PhD

Neelam Desai, MD, breast medical oncologist, hematologist, Levine Cancer Institute, Atrium Health

Karen S. Anderson, MD, PhD

Related Content

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

Related Content

Christie J. Hilton, DO

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

Francois-Clement Bidard, MD, PhD

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

David Mankoff, MD, PhD

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Professor Zefei Jiang, MD

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

FDA

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.